Business Wire

Genetic Testing Pioneer DnaNudge Signs Key Agreement With Spain’s Largest Clinical Group Quirónprevención

7.9.2021 09:00:00 EEST | Business Wire | Press release

Share

Consumer genetics testing and medical diagnostics pioneer DnaNudge today announces that it has signed a new major distributor agreement that will speed the commercial roll-out of its breakthrough rapid genetic testing solutions across Spain.

The new strategic partnership with Madrid-based Quirónprevención, grants the experienced distributor the exclusive rights to market and sell DnaNudge’s Nutrition Service, the upcoming DnaNudge Skincare service, and the first ever sample-to-result RT-PCR COVID-19 test (‘CovidNudge’). Quirónprevención is part of Quirónsalud – the leading hospital group in Spain and one of the world’s largest hospital groups. This new distributor signing is part of a significant ramp-up in the next phase of DnaNudge’s commercial growth, following its successful completion of a $60 million Series A investment round led by investment company Ventura Capital. DnaNudge’s first major fund-raising round also included participation from the world’s largest independent wealth manager Bank Julius Baer.

DnaNudge’s portable, clinical-grade point-of-care testing platform – which delivers accurate results in just over an hour, without the need for a laboratory or any manual sample pre-processing – is generating intense commercial interest from healthcare providers, private organisations and government bodies worldwide. DnaNudge has entered into a number of significant wholesale supply agreements, delivering its COVID-19 rapid, lab-free test at scale to major international healthcare companies.

Commenting on the new partnership, Regius (Royal) Professor Chris Toumazou FRS, FREng, FMedSci, CEO and co-founder of DnaNudge and founder of the Institute of Biomedical Engineering at Imperial College London said: “We are delighted to have signed this new strategic agreement with Quirón Prevención, S.L that will dramatically speed availability of our products for businesses and consumers across Spain. Our breakthrough rapid, lab-free COVID-19 test provides a highly accurate and easy-to-use solution that offers crucial reassurance and protection for people and businesses as key sectors of our societies and economies begin to build back. From public and private healthcare providers to corporate customers and the vital travel industry, the global market demand for our solutions is extremely high, and we look forward to announcing further partnerships in the very near future that will enable us to serve this interest worldwide.”

The CE-marked CovidNudge test was adapted in record time last Spring from DnaNudge’s on-the-spot consumer DNA testing service, available at its flagship store in London’s Covent Garden. DnaNudge offers the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier and more personalised choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profiles to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The company will shortly be extending its consumer genetics services into personalised skincare shopping. In July, DnaNudge was named the winner of the prestigious Royal Academy of Engineering’s MacRobert Award, the UK's longest-running national prize for engineering innovation.

Capable of a high level of multiplexing, with 72 different testing wells available on a single testing cartridge, the transformative DnaNudge testing platform offers the ability to test simultaneously for all known SARS-CoV-2 virus variants, FluA, FluB, respiratory syncytial virus (RSV), plus markers indicating genetic risk for key health conditions – all on the same test cartridge, from sample direct to result.

Ends---

About DnaNudge (http://www.dnanudge.com)

DnaNudge is the developer of the world’s first service to use consumers’ own DNA plus lifestyle factors to nudge people towards healthier choices while shopping. The DnaNudge Nutrition service analyses and maps users’ genetic profile to key nutrition-related health traits such as obesity, diabetes, hypertension and cholesterol, enabling customers to be guided by their DNA towards healthier eating. The service has been developed by world-renowned biomedical engineer Regius Professor Chris Toumazou FRS and published geneticist Dr Maria Karvela.

This ground-breaking DNA testing service created to address an epidemic – obesity and Type 2 diabetes – has been successfully adapted for the fight against a pandemic, with the development of the rapid, lab-free CovidNudge RT-PCR test. CovidNudge can accurately detect COVID-19 and other viruses in just over an hour, without the need for a laboratory, and is in use in hospitals around the world.

About Quirónprevención

Quirónprevención is the occupational health and safety consulting company part of the Fresenius Group. We take care of our customer's companies ensuring safety in their work centers and the health of the people who work in them. We are currently the leading company in our sector nationally as well internationally, with more than 5 thousand professionals taking care of 190 thousand companies and 4 million workers.

Due to this implantation, Quirónprevención is able to offer a global service, standardizing and adapting the policies of our customers in each of the countries where they operate. Innovation is another mainstay of our corporate identity and the way we work. We are aware that we live in a society that changes and updates at a dizzying speed, in which new generations and new professional profiles are being incorporated. Those we have to reach in order to continue doing our job. This requires a constant renewal and recycling, new format development and new innovative solutions that help us integrate health and safety culture at every level of the company, making attractive content.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

PRESS CONTACT for DnaNudge:
Nicky Denovan
EvokedSet PR
Email: nicky@evokedset.com
Phone: +44 (0) 118 328 2782

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr

Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye